page contents
Connect with us

Health & Lifestyle

Researchers launch two studies in Africa on new HIV vaccine

Published

on

Researchers announced the launch of two big studies in Africa on Thursday to test a new HIV vaccine and a long-acting inject-able drug, fueling hopes for better ways to protect against the virus that causes AIDS.

The start of the three-year vaccine trial involving 2,600 women in southern Africa means that for the first time in more than a decade there are now two big HIV vaccine clinical trials taking place at the same time.

The new study is testing a two-vaccine combination developed by Johnson and Johnson (J&J) with the U.S. National Institutes of Health (NIH) and the Bill and Melinda Gates Foundation.

The first vaccine, also backed by NIH, began a trial last November.

At the same time, GlaxoSmithKline’s majority-owned ViiV Healthcare unit is starting another study enrolling 3,200 women in sub-Saharan Africa to evaluate the benefit of giving injections every two months of its experimental drug cabotegravir.

The ViiV initiative, which is expected to run until May 2022, also has funding from the NIH and the Gates Foundation.

Women are a major focus in the fight against the sexually transmitted disease since in Africa they account for more than half of all new HIV infections.

ViiV is also running another large study with its long-acting injection in HIV-uninfected men and transgender women who have sex with men.

That study started in December 2016.

Although modern HIV drugs have turned the disease from a death sentence into a chronic condition and preventative drug treatment can help, a vaccine is still seen as critical in rolling back the pandemic.

The latest vaccine experiments aim to build on the modest success of a trial in Thailand in 2009, when an earlier vaccine showed a 31 per cent reduction in infections.

“We’re making progress,” said J&J Chief Scientific Officer Paul Stoffels, who believes it should be possible to achieve effectiveness above 50 per cent.

“That is the goal. Hopefully, we get much higher,” he said.

The new vaccines require one dose to prime the immune system and a second shot to boost the body’s response.

Significantly, J&J’s latest vaccine uses so-called mosaic technology to combine immune-stimulating proteins from different HIV strains, representing different types of virus from around the world, which should produce a “global” vaccine.

One reason why making an HIV vaccine has proved so difficult in the past is the variability of the virus.

Initial clinical results reported at an AIDS conference in Paris in July showed the mosaic vaccine was safe and elicited a good immune response in healthy volunteers.

Some 37 million individuals around the world currently have HIV and around 1.8 million became newly infected in 2016.

Health & Lifestyle

Cote d’Ivoire: Destroying the Killer Rice

Published

on

Authorities in Cote d’Ivoire have destroyed 18,000 tonnes of rice declared to be unfit for human consumption.

This follows tests carried out by the country’s consumer association which had demanded the government to do so after the cargo from Myanmar had been refused entry in Togo, Guinea and Ghana over quality issues.

The national and international quality control tests revealed the unfit nature of the rice.

It should be noted that most African countries depend on imports because local farmers are unable to meet the ever rising demands.

Source: Africanews

Continue Reading

Health & Lifestyle

Mali: Donkeys deliver vaccines as diseases spike with violence

Published

on

Reuters DAKAR –

With spiraling ethnic violence exposing more children in Mali to fatal diseases, health workers are using donkeys and boats to deliver life-saving vaccines, charities said on Wednesday.

In the central Mopti region – where 157 people died in one attack last month – suspected measles cases rose five-fold in one year to 98 in 2018, U.N. children’s agency UNICEF said, due to a four-fold jump in unvaccinated children to 70,000.

Motorcycles, which health workers used to reach remote villages, have been banned to reduce militant activity, forcing them to use traditional means like horses, it said.

“The problem of vaccination is directly linked to the current conflict,” said Patrick Irenge, medical coordinator for the charity Medecins Sans Frontieres (MSF), which is using cars and boats as mobile clinics to reach cut off communities.

“If there is a lull in the violence, a small window that opens, we organize a vaccination campaign.”

Last month’s massacre was the deadliest to date in a conflict between Dogon hunters and Fulani herders which has displaced tens of thousands of civilians in the West African country since it escalated last year.

Pneumonia is one of the top killers of children in Mali and it can be prevented with vaccines – as can measles – but it is too dangerous for many parents to venture out with children.

“Transport is difficult because we don’t have the means to rent a vehicle or a horse cart,” said Aissata Barry, a 34-year-old mother in the village of Kankelena, about 4 km (2.5 miles) from the nearest health center in the town of Sofara.

“There are rapists on the road. That’s what we’re afraid of,” she told the Thomson Reuters Foundation by phone, adding that one of her neighbors was raped two weeks ago.

Mamadou Kasse, a local health worker who vaccinated Barry’s children, said the number of children he can reach each day has fallen since he swapped his motorbike for an eight-hour ride in a donkey cart with a cooler full of vaccines.

Reporting by Nellie Peyton; Editing by Katy Migiro. Please credit the Thomson Reuters Foundation, the charitable arm of Thomson Reuters, that covers humanitarian news, women’s and LGBT+ rights, human trafficking, property rights, and climate change. Visit news.trust.org

Continue Reading

Facebook

Advertisement
Flag Counter
Advertisement

Trending

Copyright © 2018 Anttention Media. All rights reserved